<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-054540</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Inhaled corticosteroid therapy and bone metabolism in asthmatic children</dc:title>
<dc:description xml:lang="en">Objective: To explore the association between inhaled corticosteroids (ICS) therapy and bone metabolism.                 Patients and methods: The sample was composed of 151 children, aged between 1 and 17 years. There were 71 asthmatics treated with ICS for at least 6 months (group 1), 44 asthmatics treated occasionally with ICS during exacerbations (group 2), and 36 healthy children (group 3). Bone mineral density (BMD) and markers of bone formation and resorption were measured. These measures, as well as other related factors, were compared among groups. Regression models for osteopenia and BMD were used with the group as the independent variable adjusted by factors with differences between groups. A two-tailed level of p &lt; 0.05 was used in all tests.                 Results: No differences in BMD were found between groups 1 and 2 but significant differences were found between groups 1 and 3 (p = 0.003). No differences were found in markers of bone formation and resorption among the groups. No association was found between BMD and the type, daily dose or accumulated dose of ICS. Group 1 showed an osteopenia odds ratio relative to group 3 of 2.94 (95 % CI: 1.49-5.78) and an average reduction of BMD of 0.50 (95 % CI: 0.32-0.68) was found from group 3 to 2 and from group 2 to 1. In group 1, markers of bone resorption significantly increased in asthmatics with osteopenia compared with those without osteopenia.                 Conclusions: ICS treatment in asthmatic children seems to affect BMD. Markers of bone formation and resorption are unaffected. Osteopenia in these children could also be related to other factors that increase bone resorption</dc:description>
<dc:creator>Galván Fernández, C</dc:creator>
<dc:creator>García-Nieto, V</dc:creator>
<dc:creator>Rodríguez Hernández, P. J</dc:creator>
<dc:creator>Aguirre-Jaime, A</dc:creator>
<dc:creator>Oliva Hernández, C</dc:creator>
<dc:creator>Suárez López de Vergara, R. S</dc:creator>
<dc:creator>Allende Riera, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Explorar la asociación entre tratamiento con glucocorticoides inhalados (GCI) y metabolismo óseo.                 Pacientes y métodos: La muestra está compuesta por 151 niños entre 1 y 17 años, 71 asmáticos en tratamiento con GCI al menos durante 6 meses (grupo 1), 44 asmáticos que recibieron GCI ocasionalmente durante las crisis (grupo 2) y 36 sanos (grupo 3). Se determinó la densidad mineral ósea (DMO) y marcadores de formación y de resorción ósea. Se compararon estos valores, y factores asociados a ellos, entre los grupos. Se emplearon modelos de regresión para osteopenia y DMO con el grupo como variable independiente ajustados por factores con diferencia entre grupos. Las pruebas emplean un nivel bilateral p &lt; 0,05.                 Resultados: No se encontraron diferencias de DMO entre grupos 1 y 2, pero sí entre grupos 1 y 3 (p = 0,003). No se hallaron diferencias en los marcadores de formación, ni de resorción ósea entre grupos. La DMO no se asoció con el tipo, dosis diaria, ni acumulada de GCI.                 El grupo 1 presentó una odds ratio (OR) respecto al 3 a osteopenia de 2,94 (intervalo de confianza del 95 % [IC 95 %]: 1,49-5,78) y se obtuvo una reducción media de la z-DMO de 0,50 (IC 95 %: 0,32-0,68) en el paso del grupo 3 al 2 y del 2 al 1. En el grupo 1 los pacientes con osteopenia presentaron un aumento significativo de marcadores de resorción ósea respecto a los pacientes sin osteopenia.                 Conclusiones: El tratamiento con GCI en niños asmáticos parece afectar la DMO. Los marcadores de formación y resorción ósea no se ven afectados. La osteopenia en estos niños además podría estar relacionada con algún factor que incremente la resorción ósea</dc:description>
<dc:source>An Pediatr (Barc);66(5): 468-474, mayo 2007. ilus, tab</dc:source>
<dc:identifier>ibc-054540</dc:identifier>
<dc:title xml:lang="es">Glucocorticoides inhalados y metabolismo óseo en niños asmáticos</dc:title>
<dc:subject>^d7399</dc:subject>
<dc:subject>^d16508^s22031</dc:subject>
<dc:subject>^d308^s22044</dc:subject>
<dc:subject>^d10205^s22012</dc:subject>
<dc:subject>^d28620</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d1860^s22021</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:subject>^d24769</dc:subject>
<dc:subject>^d24543^s22021</dc:subject>
<dc:subject>^d24543^s22031</dc:subject>
<dc:subject>^d24811</dc:subject>
<dc:subject>^d1257^s22044</dc:subject>
<dc:subject>^d33421^s22073</dc:subject>
<dc:subject>^d1257^s22016</dc:subject>
<dc:subject>^d1257^s22057</dc:subject>
<dc:subject>^d1876^s22016</dc:subject>
<dc:subject>^d1887^s22012</dc:subject>
<dc:subject>^d33421^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200705</dc:date>
</metadata>
</record>
</ibecs-document>
